Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Leiomyosarcoma is a type of cancer that forms in smooth muscle. Researchers want to see if adding ADI-PEG 20 to the usual chemotherapy for leiomyosarcoma works better than chemotherapy alone. The people in this study have leiomyosarcoma that keeps growing despite treatment.
Researchers want to see how well selinexor works in people with Wilms' tumor and other solid tumors. The people in this study are children and adults with tumors that depend on a protein called XPO1. XPO1 helps cancer cells grow by getting rid of proteins that can cause those cells to die (tumor suppressor proteins).
Researchers want to see how well enfortumab vedotin works in people with adenoid cystic carcinoma. This cancer most often starts in the salivary glands and certain other glands in the body. The people in this study have adenoid cystic cancer that came back or spread after treatment.
Researchers want to see if giving additional radiation therapy to standard treatment helps people with lung cancer to live longer. The people in this study have non-small cell lung cancer (NSCLC) that cannot be removed with surgery (inoperable cancer). The standard treatment includes image-guided radiation therapy (IGRT), chemotherapy, and immunotherapy with durvalumab. 
Researchers want to find the best dose of eganelisib when used alone and with cytarabine to treat leukemia. The people in this study have acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) that has come back or keeps growing after treatment.          
This study is comparing the effectiveness of combination chemotherapy plus tucatinib and trastuzumab versus combination chemotherapy alone in people with metastatic colorectal cancer that is positive for the HER2 protein. The combination chemotherapy is called mFOLFOX6 (oxaliplatin, leucovorin or levoleucovorin, and fluorouracil) and it is a standard treatment for advanced colorectal cancer.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
